|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
5
|
|
pubmed:dateCreated |
2008-4-18
|
|
pubmed:abstractText |
There is an urgent need for therapies that slow or reverse the progression of Parkinson's disease (PD). Neurotrophic factors can improve the function of degenerating neurons and protect against further neurodegeneration, and gene transfer might be a means to deliver effectively these factors to the brain. The aim of this study was to assess the safety, tolerability, and potential efficacy of gene delivery of the neurotrophic factor neurturin.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
May
|
|
pubmed:issn |
1474-4422
|
|
pubmed:author |
pubmed-author:BakayRoy AeRA,
pubmed-author:BartusRaymond TRT,
pubmed-author:Cahn-WeinerDeborah ADA,
pubmed-author:LarsonPaul SPS,
pubmed-author:MarksWilliam JWJJr,
pubmed-author:OlanowC WarrenCW,
pubmed-author:OstremJill LJL,
pubmed-author:StarrPhilip APA,
pubmed-author:StoesslA JonAJ,
pubmed-author:TaylorRobinR,
pubmed-author:VerhagenLeonardL
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
7
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
400-8
|
|
pubmed:meshHeading |
pubmed-meshheading:18387850-Adult,
pubmed-meshheading:18387850-Aged,
pubmed-meshheading:18387850-Dependovirus,
pubmed-meshheading:18387850-Dose-Response Relationship, Drug,
pubmed-meshheading:18387850-Drug Delivery Systems,
pubmed-meshheading:18387850-Female,
pubmed-meshheading:18387850-Gene Therapy,
pubmed-meshheading:18387850-Genetic Vectors,
pubmed-meshheading:18387850-Humans,
pubmed-meshheading:18387850-Male,
pubmed-meshheading:18387850-Middle Aged,
pubmed-meshheading:18387850-Motor Activity,
pubmed-meshheading:18387850-Neurturin,
pubmed-meshheading:18387850-Parkinson Disease,
pubmed-meshheading:18387850-Putamen
|
|
pubmed:year |
2008
|
|
pubmed:articleTitle |
Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial.
|
|
pubmed:affiliation |
Department of Neurology, University of California, San Francisco, San Francisco, CA 94143-0138, USA. william.marks@ucsf.edu
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase I
|
